Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06532565 · ClinicalTrials.gov registry record · Phase 1
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 154
- Enrollment target
- 6
- Study locations
NCT06532565: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Gilead Sciences.
NCT06532565 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 154 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (22% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06532565, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 154 participants
- Enrollment target
- 6
- Study locations
Study Summary
The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of GS-2121 as monotherapy and GS-2121 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of GS-2121 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Zimberelimab
- DRUG GS-2121
Study Locations (6)
Other
- The Ottawa Hospital Cancer Centre - Ottawa
- Princess Margaret Cancer Centre - Toronto
California
- Stanford Cancer Center - Palo Alto
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Texas
- NEXT Oncology - San Antonio
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2024-07-26 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
What NCT06532565 shows while recruiting
NCT06532565 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Zimberelimab is the first listed.
NCT06532565 lists 6 locations in 5 states (Other, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06532565 about?
NCT06532565 is a clinical study titled "Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors". The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of GS-2121 as...
What is the current status of trial NCT06532565?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2024-07-26. Estimated completion is 2028-06.
What conditions does trial NCT06532565 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06532565?
The interventions under investigation include: Zimberelimab (DRUG), GS-2121 (DRUG).
Who is sponsoring clinical trial NCT06532565?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06532565 being conducted?
This trial has 6 study locations across California, Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06532565's enrollment target sits among peer trials
154 58th of 144 higher than 87 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI